BMS combo would gain heft in melanoma space, say analysts

The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.

Grand Prix drought ends, but questions persist

The inspirational value is clear for Lions Health attendees, but there is still confusion about what good looks like for branded pharma campaigns, and how ...

Patient Engagement: All Grown Up—Patient Engagement Comes of Age

Patient engagement has evolved from something nice to do to an essential part of the pharma marketer's toolbox. Sarah ­Mahoney ­reviews the important ­milestones in ...

Patients in Clinical Trials: Fifty Shades of Hay

Hunting for qualified clinical research subjects can be like finding the proverbial needle in the haystack. Until, that is, you find where the needled haystacks ...

Latest

Havas Health acquires London-based PR shop

Havas Health acquires London-based PR shop

Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Five things for pharma marketers to know: Friday, June 26

Five things for pharma marketers to know: Friday, June 26

Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday

You Have 100 Days To Make An Impact. What Are You Waiting For?

You Have 100 Days To Make An Impact. What Are You Waiting For?

Just landed a new job? You've got 100 days to make an impression. Here are some suggestions.

Myelin acquires agencies in Chicago and Atlanta

Myelin acquires agencies in Chicago and Atlanta

Fourth and fifth members of network add healthcare advertising and PR expertise.

Five things for pharma marketers to know: Wednesday, June 24

Five things for pharma marketers to know: Wednesday, June 24

AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.

Treato bolsters social-media insight

The consumer-insights firm said it's debuting a listening feature that will make it harder for pharma to ignore Twitter, Reddit and the other big social platforms.

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Studies show blood thinner antidotes work

Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.

Could Marketing in Schools Help Save America's Health?

Could Marketing in Schools Help Save America's Health?

With an eye on the bottom line, hospitals and their marketing firms traditionally haven't spent much time on school campuses.

Five things for pharma marketers to know: Monday, June 22

Five things for pharma marketers to know: Monday, June 22

AstraZeneca, DigitasLBI New York take top prize in pharma category at Cannes Lions Health; Teva buys a stake in Mylan; Shire tops pharma reputation survey.

Pharma at Cannes: C'est la Vie

Pharma at Cannes: C'est la Vie

It's not only a venue to gain creative inspiration, but a good place to scout talent, and there are no lack of strategic meetings underway in Cannes.

Mobile's role in healthcare is still experimental

Mobile's role in healthcare is still experimental

Mobile app makers shared insights about how to improve people's health and change behavior at the Lions Health festival.

Agency Spotlight


Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.